Wegovy, one of the most well-known GLP-1 medications, has arrived in New Zealand. Best known for its role in weight management, it is now part of the conversation not only for metabolic health but also for sleep.
At Auckland Sleep, we make sleep a priority, and we are always interested in new treatments that could affect how well New Zealanders rest. While Wegovy was not designed as a sleep medication, early research suggests that GLP-1s may support sleep indirectly, particularly for people living with obstructive sleep apnea.
What is Wegovy?
Wegovy is the brand name for semaglutide, a GLP-1 receptor agonist that mimics a natural hormone involved in appetite and blood sugar control. Originally approved for treating type 2 diabetes under the name Ozempic, Wegovy is now endorsed for weight management in adults, including in New Zealand via Medsafe’s approval in June 2025.
How weight and sleep apnea connect
Excess weight is one of the strongest risk factors for obstructive sleep apnea, a condition where the airway narrows or collapses during sleep. This disrupts rest, lowers oxygen levels, and places strain on the heart and body. Clinical studies have found that GLP-1 medications like Wegovy may reduce the severity of sleep apnea by helping patients lose weight, which in turn eases airway obstruction.
Dr Sumit Samant, founder of Auckland Sleep, explains: “We know that even modest weight loss can improve sleep apnea symptoms for some patients. Wegovy adds another tool in the toolkit, but it should be considered alongside established treatments such as CPAP, oral appliances, or surgery when needed.”
What This Means for Kiwis
With Wegovy accessible locally, Kiwis managing their weight may also see gains in sleep quality. Remember, getting quality rest isn’t just emotionally revitalizing, it impacts heart health, resilience, and daily energy levels.
Anitha Patel, our Insomnia Specialist, adds:
“Wegovy is not a silver bullet, but for those suited to it, used alongside proper clinical guidance, it can be part of a broader health-driven approach to improving sleep.”
Important Things to Note
- Non-funded medication: Wegovy is not subsidised by Pharmac, meaning patients typically cover the full cost, which in NZ can be $450-$600 per month.
- Lifestyle remains key: Wegovy must be complemented by a reduced-calorie diet and physical activity for best outcomes.
- Potential side effects: Like other GLP-1s, Wegovy can cause nausea, gastrointestinal upset, or dehydration. Staying well hydrated is important, and you should always consult with your GP before starting.
How Auckland Sleep Can Help
Wegovy introduces new possibilities, but it’s not a universal solution. At Auckland Sleep, we’re the authority in sleep health, embracing a whole-person approach. We blend clinical care, lifestyle support, and personalised guidance to help you discover what truly supports your sleep.
Ready to explore how Wegovy or lifestyle changes could affect your rest? Reach out to our team for tailored, evidence-based support.
